Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
RayzeBio, Inc.
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05477576CT.gov Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | — | Recruiting | — | — | — |
NCT02973204CT.gov Circulating Tumor Cells and Tumor DNA in HCC and NET | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lanreotide (this asset) | RayzeBio, Inc. | P3 | CCC · 54 |
| Irinotecan | First Affiliated Hospital Xi'an Jiaotong University | P4 | BB |
| Cabozantinib | Fox Chase Cancer Center | P3 | BB |
| Fluorouracilum | ITM Solucin GmbH | P3 | BB |
| Surufatinib | Shanghai Changzheng Hospital | P3 | BB |
| Oxodotreotide | Fundación de investigación HM | P3 | BB |
| Everolimus | Exelixis | P3 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | B |
| Carboplatin | First Affiliated Hospital Xi'an Jiaotong University | P4 | B |
+42 more in the Neuroendocrine Neoplasm cohort
Other indications for Lanreotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphocele | — | P3 | BB · 64 |
| Malignant Endocrine Neoplasm | — | P3 | BB · 64 |
| Non-Functional Pancreatic Neuroendocrine Tumor | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lanreotide in Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lanreotide-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →